Hôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires
|
|
- Catherine Arnold
- 8 years ago
- Views:
Transcription
1 Hôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires Prof. J. Philippe
2 Effect of estrogens on glucose metabolism : Fasting Glucose, HbA1c and C-Peptide C in subjects with NIDDM after treatment with estradiol and placebo according to (8) Variable Baseline After treatment p-value Glucose (mmol/l) Estradiol 12.1 ±.4.9 ±.4 P <.1 Placebo 12.2 ± ±.4 HbA1c (%) Estradiol 8.7 ± ±.2 P <.1 Placebo 8.5 ±.2 9. ±.3 C-Peptide (nmol/l) Estradiol 1.29 ± ±.11 P <.1 Placebo 1.21 ± ±.13
3 Glucose level and coronary heart disease rates in the Honolulu Heart Study (12-Year Follow-up)* Postchallenge Glucose Level Fatal Coronary Heart Disease mmol/l % Total Coronary Heart Disease * The study included 6394 Japanase-American men (exclusion criteria were previous cardiovascular disease, treated hypertension, and known diabetes) and had a 12-year, age-adjusted incidence rate per 1.
4 Crude 22 years cardiovascular and noncardiovascular mortality according to fasting blood glucose quartiles. Error bars indicate 95 % CI 25 Cardiovascular mortality Non-cardiovascular mortality 2 22 Years Mortality (%) Quartile I : mg/dl Quartile II : mg/dl Quartile III : 8-85 mg/dl Quartile IV : mg/dl Fasting Blood Glucose
5 n Mean All subjects Men Women Non menopausal Menopausal Men Age n Mean All subjects Age n Mean Women Age n Mean
6 Anthropometric variables and blood pressure before and after treatment with estradiol and placebo (mean ± SEM; n = 25) 2 mg 17β-estradiol 3 months - 1 mg norethisterone acetate 1d Variables Baseline After treatment P - val Body weight (kg) Estradiol 82.1 ± ± 3.2 P <.1 Placebo 83.5 ± ± 3.2 Body fat (kg) Estradiol 38. ± ± 2. P <.5 Placebo 4.1 ± ± 2.2 Lean body mass (kg) Estradiol 43.9 ± ± 1.4 ns Placebo 43.5 ± ± 1.4 Waist/hip ratio Estradiol.96 ±.2.96 ±.2 ns Placebo.96 ±.2.96 ±.2 SBP (mmhg) Estradiol 139 ± ± 3 ns Placebo 14 ± ± 3 DBP(mmHg) Estradiol 73 ± 2 72 ± 72 ns Placebo 74 ± ± 2 SBP, Systolic blood pressure; DBP, diastolic blood pressure, ns, not significant p-values for comparison between changes during estradiol treatment vs. placebo treatment
7 Incidence rate/ Fasting plasma glucose Quintiles Incidence rate/ hour plasma glucose P < Quintiles Incidence of CVD according to fasting and 2-hour 2 plasma glucose and insulin concentrations Fasting plasma insulin 2- hour plasma insulin Incidence rate/ Quintiles Incidence rate/ P < Quintiles
8 Cumulative hazard curves for ADA fasting glucose criteria and WHO 2h glucose criteria adjusted by age, sex, and study center Fasting glucose classification Known diabetes Diabetes by ADA criteria Impaired fasting glucose Normal 2 h glucose classification Known diabetes Diabetes by ADA criteria Impaired fasting glucose Normal Cumulative hazard Cumulative hazard Follow-up (years) Follow-up (years)
9 Age adjusted 22 years cumulative cardiovascular mortality comparing fasting blood glucose quartiles I-III I III ( ( 85 mg/dl) with quartile IV (> 85 mg/dl) 22 years cumulative cardiovascular mortality (%) Years of follow-up
10 The relationship between non-diabetic glycemia and ischaemic heart disease (IHD) mortality in men ( );( premenopausal women ( );( and postmenopausal women ( ).( Non-diabetic men and women aged 4-79 years were followed for an average of 14 years. (Schwidt-Nave et al. Am J Epidemiol 1991; 133: )
11 The significance of glucose concentrations as a risk factor for chronic disease. Plasma glucose concentrations above the diabetic cut off are associated with an increasing risk of cardiovascular and microvascular disease; levels above the IGT cut off are associated with an increasing risk of diabetes; and elevated levels above some, s as yet undefined, "dysglycaemic"" cut off are associated with an increasing risk of cardiovascular disease.
12 Blood lipids before and after treatment with estradiol and placebo (mean ± SEM; n = 25) Variables Baseline After treatment P - val Cholesterol (mmol/l) Estradiol 5.7 ± ±.1 P <.1 Placebo 5.9 ± ±.2 HDL-C (mmol/l) Estradiol 1.1 ± ±.6 P <.1 Placebo 1.11 ± ±.5 LDL-C (mmol/l) Estradiol 3.74 ± ±.14 P <.1 Placebo 3.54 ± ±.15 Triglycerides (mmol/l) Estradiol 2.4 ± ±.17 ns Placebo 2.39 ± ±.26 HDL-C, High density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol p-values for comparison between changes during estradiol treatment vs. placebo treatment
13 2 R=-6.4, p<.5 dhba1c (% ) 1-1
14 Changes in triglycerides in post-menopausal women receiving either no treatment, transdermal oestradiol-17 17β.5 mg daily with cyclical transdermal norethisterone acetate.25 mg daily, or oral conjugated equine oestrogens.625 mg daily with cyclical oral dl-norgestrel.15 mg daily. 3A, oestrogen alone phase; 3B, combined phase, 6, combined phase. (*p <.5). Control Transdermal Oral 2 15 * 1 % change Cycle : * E EP EP E EP EP Oestradiol+desogestrel Tibolone Danazol
15 Changes in high density lipoprotein (HDL) subfractions and apolipoproteins AI and AII in post-menopausal women receiving either transdermal oestradiol-17 17β.5 mg daily with cyclical transdermal norethisterone acetate.25 mg daily,or oral conjugated equine oestrogens.625 mg daily with cyclical oral dl-norgestrel.15 mg daily HDL2 HDL3 Transdermal Oral Transdermal Oral % change -5-1 % change Cycle : 3A 3B 6 3A 3B 6-2 Cycle : 3A 3B 6 3A 3B 6 3A : oestrogen alone phase - 3B : combined phase - 6 : combined phases ** p<.1; *** p<.1
16 Changes in high density lipoprotein (HDL) subfractions and apolipoproteins AI and AII in post-menopausal women receiving either transdermal oestradiol-17 17β.5 mg daily with cyclical transdermal norethisterone acetate.25 mg daily,or oral conjugated equine oestrogens.625 mg daily with cyclical oral dl-norgestrel.15 mg daily apo A1 apo AII Transdermal Oral Transdermal Oral % change -5-1 % change Cycle : 3A 3B 6 3A 3B 6-2 Cycle : 3A 3B 6 3A 3B 6 3A : oestrogen alone phase - 3B : combined phase - 6 : combined phases ** p<.1; *** p<.1
17 Changes in total cholesterol in post-menopausal women receiving either no treatment, trandermal oestradiol- 17β.5 mg daily with cyclical transdermal norethisterone acetate.25 mg daily,, or oral conjugated equine oestrogens.625 mg daily with cyclical oral dl-norgestrel.15 mg daily. Change from baseline (% ) Total cholesterol 3 6 3A 3B 6 3A 3B 6 3A : oestrogen alone phase - 3B : combined phase - 6 : combined phases *** p<.1
18 Cholesterol Months LDL-Cholesterol Months % Change in initial value % Change in initial value
19 HDL-Cholesteroll Months Apo A Months % Change in initial value % Change in initial value
20 Lipoprotein(a) Months Triglycerides Months % Change in initial value % Change in initial value
21 Effect of menopause on lipids and lipoproteins. HDL3 cholesterol HDL2 cholesterol HDL cholesterol LDL cholesterol Triglyce ride s Total cholesterol % change 542 healthy, non obese caucasian females 18-7 yrs LDL, low density lipoproteins; HDL, high density lipoproteins
22 Effects of sex steroids on lipid metabolism. Width of lines indicate the rate of cholesterol traffic under influence of estrogen (L) or progestin/androgen (R). Question marks indicate effects for which documentation is uncertain or unclear ESTROGEN PROGESTIN / ANDROGEN LPL ( ) Bile Acids Chol Diet Chylomicrons Remnants? E HTGL B/E VLDL Remnants LDL LTP? HDL2 B/E FC HDL3 LPL (?) Bile Acids Chol Diet Chylomicrons Remnants? E HTGL VLDL Remnants B/E LDL LTP?? HDL2 B/E FC HDL3 CA/CDA +DC CA/CDA +DC
23 Effect of treatment with Placebo or 17β -Estradiol on concentrations of plasma lipids, lipoproteins, plasma nonesterified Fas,, C Peptide, and HbA1c (6 weeks) Placebo (n=2) Baseline Estradiol (n=2) Absolute and percentage changes after treatment p Placebo (n=2) Estradiol (n=2)= p TC, mmol/l 5.28 ±.66 ( ) LDL-C, mmol/l 3.36 ±.68 ( ) 5.25 ±.6 ( ) 3.3 ±.74 ( ).81.4 ±.46 (1%±9%).68.6 ±.38 (2 %±11%) -.28 ±.44 (-5%±8%) -48 ±.44 (-14 %±12 %).2 (.4).1 (.1) HDL-C, mmol/l 1.2 ±.3 ( ) 1.2 ±.47 ( ).88.3 ±.16 (3 %± 13 %).26 ±.18 (23 %±14 %).2 (.1) HDL 2 -C, mmol/l.36 ±.19 ( ).41 ±.29 ( ).89.2 ±.12 (11% ± 35 %).2 ±.17 (6%±44%).7 (.7) HDL 3 -C, mmol/l.84 ±.14 ( ).79±.21 ( ).47.2 ±.8 (3 % ± 9 %).7 ±.11 (11 % ± 15 %).14 (.1) VLDL-C, mmol/l.64 ±.35 ( ).69±.43 ( ) ±.2 (-11 % ±29 %) -.6 ±.25 (-11 % ± 37 %).61 (.7)
24 Effect of treatment with Placebo or 17β -Estradiol on concentrations of plasma lipids, lipoproteins, plasma nonesterified Fas,, C Peptide, and HbA1c (6 weeks) TGs, mmol/l VLDL TGs, mmol/l Placebo (n=2) 1.53 ±.83 ( ) 1.6 ±.63 ( ) ApoA-1, g/l 1.44 ±.18 ( ) ApoB, g/l 1.27 ±.28 ( ) Nonesterified Fas, mmol/l.36 ±.21 ( ) C peptide, nmol/l.54 ±.38 (-1.41) HbA1c, % 8.1 ± 1.6 ( ) Baseline Estradiol (n=2) 1.74 ±.95 ( ) 1.9 ±.83 ( ) 1.39 ±.28 ( ) 1.26 ±.36 ( ).47 ±.32 ( ).38 ±.39 (-1.68) 8.7 ± 1.5 ( ) Absolute and percentage changes after treatment p Placebo (n=2) Estradiol (n=2)= p.48.8 ±.48 (4 % ± 24 %).7.2 ±.32 (2 % ± 31 %).68.5 ±.1 (3 % ± 7 %).89.3 ±.14 (2 % ± 11 %).3.5 ±.29 (29 % ±113 %) ±.42 (8 %± 9 %) ±.45 (-4% ± 5 %).5 ±.62 (13 % ± 59 %) ±.32 (4 % ± 41 %).22 ±.13 (17 %± 1 %) -13±.13 (-9 % ± 9 %) -.2 ±.37 (37 % ± 15%) -.14±.33 (-16 % ± 89 %) -.66 ±.67 (-7 %± 7 %).65 (.66).85 (.67).1 (.1).4 (.1).79 (.62).26 (.1).2 (.3)
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,
More informationMY TYPE 2 DIABETES NUMBERS
BLOOD SUGAR MANAGEMENT GUIDE MY TYPE 2 DIABETES NUMBERS Understanding and Tracking the ABCs of Type 2 Diabetes 1 BLOOD MY TYPE SUGAR 2 DIABETES MANAGEMENT ABC NUMBERS GUIDE When you have type 2 diabetes,
More informationHow To Treat Dyslipidemia
An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia Introduction Executive Summary The International Atherosclerosis Society (IAS) here updates
More informationImproving cardiometabolic health in Major Mental Illness
Improving cardiometabolic health in Major Mental Illness Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Metabolic
More informationEducation. Panel. Triglycerides & HDL-C
Triglycerides & HDL-C Thomas Dayspring, MD, ACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry of New Jersey Attending in Medicine: St Joseph s s Hospital, Paterson, NJ Certified
More informationGuidelines for the management of hypertension in patients with diabetes mellitus
Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes
More informationMargarines and Heart Disease. Do they protect?
Margarines and Heart Disease Do they protect? Heart disease Several studies, including our own link margarine consumption with heart disease. Probably related to trans fatty acids elevate LDL cholesterol
More informationClinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D.
Clinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D. Associate Investigator Palo Alto Medical Foundation Research Institute Consulting Assistant
More informationProtein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075
Title: Protein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075 Investigator: Institution: Gail Gates, PhD, RD/LD Oklahoma State University Date
More informationStatins and Risk for Diabetes Mellitus. Background
Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration
More informationWhy is HDL Cholesterol Low in People with Insulin Resistance and Type 2 Diabetes Mellitus?
Why is HDL Cholesterol Low in People with Insulin Resistance and Type 2 Diabetes Mellitus? Henry Ginsberg, MD Columbia University College of Physicians and Surgeons Henry Ginsberg: Disclosures Research
More informationHigh Blood Cholesterol
National Cholesterol Education Program ATP III Guidelines At-A-Glance Quick Desk Reference 1 Step 1 2 Step 2 3 Step 3 Determine lipoprotein levels obtain complete lipoprotein profile after 9- to 12-hour
More informationMultiple comorbidities: additive and predictive of cardiovascular risk. Peter M. Nilsson Lund University University Hospital Malmö, Sweden
Multiple comorbidities: additive and predictive of cardiovascular risk Peter M. Nilsson Lund University University Hospital Malmö, Sweden Clinical outcomes: major complications of CVD Heart Attack/ACS
More informationHDL Cholesterol Subfractions and the Effect of Testosterone Replacement in Hypogonadism
HDL Cholesterol Subfractions and the Effect of Testosterone Replacement in Hypogonadism E. Bolu 1, A. Sonmez 1, S. Tapan 2, A. Taslipinar 1, A. Aydogdu 1, C. Meric 1, Y. Basaran 1, G. Uckaya 1, M. Serdar
More informationYour healthcare provider has ordered a Boston Heart Cardiac Risk Assessment
Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment What does that mean for you? Your healthcare provider has determined that you may be at risk for cardiovascular disease (CVD).
More informationTYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
More informationUnderstanding diabetes Do the recent trials help?
Understanding diabetes Do the recent trials help? Dr Geoffrey Robb Consultant Physician and Diabetologist CMO RGA UK Services and Partnership Assurance AMUS 25 th March 2010 The security of experience.
More informationTechnology Assessment
Technology Assessment Lifestyle Interventions for Four Conditions: Type 2 Diabetes, Metabolic Syndrome, Breast Cancer, and Prostate Cancer Technology Assessment Program Prepared for: Agency for Healthcare
More informationThe WHI 12 Years Later: What Have We Learned about Postmenopausal HRT?
AACE 23 rd Annual Scientific and Clinical Congress (2014) Syllabus Materials: The WHI 12 Years Later: What Have We Learned about Postmenopausal HRT? JoAnn E. Manson, MD, DrPH, FACP, FACE Chief, Division
More informationMetabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007
Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering
More informationAn Overview and Guide to Healthy Living with Type 2 Diabetes
MEETING YOUR GOALS An Overview and Guide to Healthy Living with Type 2 Diabetes MEETING YOUR GOALS This brochure was designed to help you understand the health goals to live a healthy lifestyle with type
More informationThe Women s Health Initiative where are we a decade later?
The Women s Health Initiative where are we a decade later? Henry G. Burger MIMR-PHI Institute & Jean Hailes for Women s Health, Melbourne, Australia Disclosures: Henry Burger Sources of Funding Pharmaceutical
More informationDesign and principal results
International Task Force for Prevention Of Coronary Heart Disease Coronary heart disease and stroke: Risk factors and global risk Slide Kit 1 (Prospective Cardiovascular Münster Heart Study) Design and
More informationSerum testosterone and short-term mortality in men with acute myocardial infarction
ORIGINAL ARTICLE Cardiology Journal 2010, Vol. 17, No. 3, pp. 249 253 Copyright 2010 Via Medica ISSN 1897 5593 Serum testosterone and short-term mortality in men with acute myocardial infarction Constantin
More informationMANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING
More information1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME
1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME Izet Aganović, Tina Dušek Department of Internal Medicine, Division of Endocrinology, University Hospital Center Zagreb, Croatia 1 Introduction The metabolic syndrome
More informationQuantifying Life expectancy in people with Type 2 diabetes
School of Public Health University of Sydney Quantifying Life expectancy in people with Type 2 diabetes Alison Hayes School of Public Health University of Sydney The evidence Life expectancy reduced by
More informationCardiovascular Effects of Drugs to Treat Diabetes
Cardiovascular Effects of Drugs to Treat Diabetes Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies Clinical Trials:
More informationThe South Asian Indian Women s s Weight Loss Study. Latha Palaniappan, MD, MS BIRCWH Scholar October 20, 2005
The South Asian Indian Women s s Weight Loss Study Latha Palaniappan, MD, MS BIRCWH Scholar October 20, 2005 South Asian Emigrants and second generation from India Bhutan Bangladesh Maldives Nepal Pakistan
More informationREDESIGNING TREATMENT STRATEGIES IN TYPE 2 DIABETES BY TREATMENT INTENSIFICATION AND PATIENT EDUCATION LAKSHMI SUBRMANYA RAO
REDESIGNING TREATMENT STRATEGIES IN TYPE 2 DIABETES BY TREATMENT INTENSIFICATION AND PATIENT EDUCATION by LAKSHMI SUBRMANYA RAO B Pharmacy, Rajiv Gandhi University of Health Sciences, India 2008 M S in
More informationCardiovascular Disease Risk Factors
Cardiovascular Disease Risk Factors Risk factors are traits and life-style habits that increase a person's chances of having coronary artery and vascular disease. Some risk factors cannot be changed or
More informationDiabetes and Heart Disease
Diabetes and Heart Disease Diabetes and Heart Disease According to the American Heart Association, diabetes is one of the six major risk factors of cardiovascular disease. Affecting more than 7% of the
More informationInsulin Resistance and PCOS: A not uncommon reproductive disorder
Insulin Resistance and PCOS: A not uncommon reproductive disorder Joyce L. Ross, MSN, CRNP, CS, FNLA, FPCNA Diplomate Accrediation Council for Clinical Lipidology President Preventive Cardiovascular Nurses
More informationEvaluation of Non-HDL-Cholesterol/HDL-cholesterol ratio as a predictor of coronary artery disease
Journal homepage: http://www.journalijar.com INTERNATIONAL JOURNAL OF ADVANCED RESEARCH RESEARCH ARTICLE Evaluation of Non-HDL-Cholesterol/HDL-cholesterol ratio as a predictor of coronary artery disease
More informationPlasma Testosterone Level in Male Patients with Metabolic Syndrome
Med. J. Cairo Univ., Vol. 77, No. 1, June: 351-357, 2009 www.medicaljournalofcairouniversity.com Plasma Testosterone Level in Male Patients with Metabolic Syndrome NASHWA EL-SARRAF, M.D. and AMR EL-HADIDY,
More informationFebruary 1, 2014 RESTORING STRENGTH AND VITALITY THROUGH HORMONES FACTS, FANTASIES, POSSIBILITIES, AND PITFALLS
February 1, 2014 RESTORING STRENGTH AND VITALITY THROUGH HORMONES FACTS, FANTASIES, POSSIBILITIES, AND PITFALLS Calvin Hirsch, MD Professor of Clinical Internal Medicine (Geriatrics) UC Davis School of
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationWelchol (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
More informationVascular Risk Reduction: Addressing Vascular Risk
Vascular Risk Reduction: Addressing Vascular Risk Vascular Risk Reduction (VRR) Welcome! Presentation & Activities Focus: Managing known risk factors for vascular disease. Engage, collaborate and have
More informationBody Composition & Longevity. Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ
Body Composition & Longevity Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ LONGEVITY Genetic 25% Environmental Lifestyle Stress 75% BMI >30 OBESE 25-30 OVERWEIGHT 18-25 NORMAL WEIGHT 18
More informationPostmenopausal Hormone Replacement Therapy and Cardiovascular Disease
This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or a basis for reimbursement and coverage policies. AHRQ
More informationThe Prevalence and Determinants of Undiagnosed and Diagnosed Type 2 Diabetes in Middle-Aged Irish Adults
The Prevalence and Determinants of Undiagnosed and Diagnosed Type 2 Diabetes in Middle-Aged Irish Adults Seán R. Millar, Jennifer M. O Connor, Claire M. Buckley, Patricia M. Kearney, Ivan J. Perry Email:
More informationSystolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and
More informationMortality Assessment Technology: A New Tool for Life Insurance Underwriting
Mortality Assessment Technology: A New Tool for Life Insurance Underwriting Guizhou Hu, MD, PhD BioSignia, Inc, Durham, North Carolina Abstract The ability to more accurately predict chronic disease morbidity
More informationHow To Understand And Understand The Concept Of Intermediate Hyperglycaemia
Overdiagnosis and the Epidemic of Pre-Diabetes John S. Yudkin Emeritus Professor of Medicine, University College London Outline The concept of Intermediate Hyperglycaemia - Predicting future diabetes
More informationObesity in the United States Workforce. Findings from the National Health and Nutrition Examination Surveys (NHANES) III and 1999-2000
P F I Z E R F A C T S Obesity in the United States Workforce Findings from the National Health and Nutrition Examination Surveys (NHANES) III and 1999-2000 p p Obesity in The United States Workforce One
More informationAggressive Lowering of Blood Pressure in type 2 Diabetes Mellitus: The Diastolic Cost
Aggressive Lowering of Blood Pressure in type 2 Diabetes Mellitus: The Diastolic Cost Naftali Stern Institute of Endocrinology, Metabolism and Hypertension Tel Aviv -Sourasky Medical Center and Sackler
More informationDISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
More informationAssessment and Management of Cardiovascular Risks in Women
Checklist for effective cardiovascular risk evaluation ESC Task Force on Gender Initial consultation Family history Cigarettes/day Alcohol consumption Menopausal status Age Chronic kidney disease Diabetes
More informationHow To Know If You Have Microalbuminuria
3 PREVALENCE AND PREDICTORS OF MICROALBUMINURIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A CROSS-SECTIONAL OBSERVATIONAL STUDY Dr Ashok S Goswami *, Dr Janardan V Bhatt**; Dr Hitesh Patel *** *Associate
More informationPart 7. Lipid Control in Type 2 Diabetes
National Evidence Based Guidelines for the Management of Type 2 Diabetes Mellitus Part 7 Lipid Control in Type 2 Diabetes Prepared by the Australian Centre for Diabetes Strategies Prince of Wales Hospital,
More informationInformation About Hormonal Treatment for
Information About Hormonal Treatment for Trans Men Leighton J Seal PhD FRCP Consultant Endocrinologist, Gender Identity Clinic, West London Mental Health NHS Trust (Charing Cross) Leighton J Seal 1 Patient
More informationDiabetes and Stroke. Understanding the connection between diabetes and the increased risk of stroke
Diabetes and Stroke Understanding the connection between diabetes and the increased risk of stroke Make the Connection Almost 26 million people in the U.S. roughly 8 percent of the population have diabetes.
More informationPrevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012
Prevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012 In 2002, SETMA began a relationship with Joslin Diabetes
More informationAntiretroviral treatment is Associated with increased Arterial Stiffness in Sub- Saharan African HIV-1 Infected Patients: A cross- Sectional Study
Antiretroviral treatment is Associated with increased Arterial Stiffness in Sub- Saharan African HIV-1 Infected Patients: A cross- Sectional Study Titus F. Msoka Supervisors Marceline van Furth Yvo Smulders
More informationAn Interview with Gerald Reaven: Syndrome X : The Risks of Insulin Resistance
An Interview with Gerald Reaven: Syndrome X : The Risks of Insulin Resistance Gerald Reaven, M.D., is Professor Emeritus (Active) of Medicine at Stanford University. He has served as director of the Division
More informationCardiovascular Disease in Diabetes
Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality
More informationDIABETES YOUR GUIDE TO
YOUR GUIDE TO DIABETES b What is diabetes? b Type 2 diabetes prevention b Prevention checklist b Living with diabetes b Complications b Terms to know b Resources To promote and protect the health of Canadians
More informationHypertension and Diabetes Status. 2011 Bangladesh Demographic and Health Survey
Hypertension and Diabetes Status 2011 Bangladesh Demographic and Health Survey Methodology and Sampling Total 18,000 households were selected nationwide (207 in urban and 393 in rural areas) One-third
More informationTHE THIRD REPORT OF THE EXpert
SPECIAL COMMUNICATION Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
More informationThe Women s Health Initiative: The Role of Hormonal Therapy in Disease Prevention
The Women s Health Initiative: The Role of Hormonal Therapy in Disease Prevention Robert B. Wallace, MD, MSc Departments of Epidemiology and Internal Medicine University of Iowa College of Public Health
More informationHypogonadism and Testosterone Replacement in Men with HIV
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Hypogonadism and Testosterone Replacement in Men with HIV Stephanie T. Page, MD, PhD Robert B. McMillen Professor in Lipid Research, Associate Professor of
More informationUnderstanding the Entire Lipid profile Thomas Dayspring MD, FACP
There is only one absolute in atherosclerosis: sterols (predominantly cholesterol) entering the artery wall and being internalized by macrophages, creating foam cells (the histologic diagnostic marker
More informationThe Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery
The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery Michael E. Farkouh, MD, MSc Peter Munk Chair in Multinational Clinical Trials Director, Heart and Stroke
More informationMISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY
MISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY In order to improve the efficiency of PINNACLE Registry data analytics, a missing data analysis has been conducted on PINNACLE Registry data
More informationGetting Off the Chronic Disease Merry-Go-Round: What s the Weight of the Research?
Getting Off the Chronic Disease Merry-Go-Round: What s the Weight of the Research? Jody Dushay, MD MMSc Beth Israel Deaconess Medical Center Boston, MA Session 445 No disclosures Disclosure Jody Dushay,
More informationdefinition and diagnosis of diabetes mellitus and intermediate hyperglycemia Report of a WHO/IDF Consultation
definition and diagnosis of diabetes mellitus and intermediate hyperglycemia Report of a WHO/IDF Consultation WHO Library Cataloguing-in-Publication Data Definition and diagnosis of diabetes mellitus and
More informationTestosterone for women, who when and how much?
Medicine, Nursing and Health Sciences Testosterone for women, who when and how much? Susan R Davis MBBS FRACP PhD Women s Health Research Program School of Public Health Monash University Melbourne Medicine,
More informationAbsolute cardiovascular disease risk management
Quick reference guide for health professionals Absolute cardiovascular disease risk management This quick reference guide is for use by health professionals for primary prevention of cardiovascular disease
More informationCORPORATE HEALTH LOWERING YOUR CHOLESTEROL & BLOOD PRESSURE
CORPORATE HEALTH LOWERING YOUR CHOLESTEROL & BLOOD PRESSURE What is Cholesterol? What s wrong with having high cholesterol? Major risk factor for cardiovascular disease Higher the cholesterol higher the
More informationManaging diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ)
Managing diabetes in the post-guideline world Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ) Overview Pathogenesis of T2DM Aims of treatment The place of glycaemic control Strategies to improve glycaemic
More informationOverview and update of modern type 2 Diabetes philosophy and management. Dr Steve Stanaway Consultant Endocrinologist BCU
Overview and update of modern type 2 Diabetes philosophy and management Dr Steve Stanaway Consultant Endocrinologist BCU Diabetes economics 2009: 2.6M adults with DM in UK (90% type 2) 2025: est. > 4M
More informationCorrespondence should be addressed to Farid Saad; farid.saad@bayer.com
International Journal of Endocrinology, Article ID 683515, 15 pages http://dx.doi.org/10.1155/2014/683515 Clinical Study Effects of Long-Term Testosterone Therapy on Patients with Diabesity : Results of
More informationDR. Trinh Thi Kim Hue
TYPE 2 DIABETES IN THE CHILD AND ADOLESCENT DR. Trinh Thi Kim Hue CONTENTS Definition Diagnosis Treatment Comorbidities and Complications Comorbidities and Complications Screening for T2D References DEFINITION
More informationHormone replacement therapy:
www.bpac.org.nz keyword: hrt Hormone replacement therapy: latest evidence and treatment recommendations Key advisor: Dr Helen Roberts, Senior Lecturer, Department of Obstetrics and Gynaecology, Faculty
More informationWHAT DOES DYSMETABOLIC SYNDROME MEAN?
! WHAT DOES DYSMETABOLIC SYNDROME MEAN? Dysmetabolic syndrome (also referred to as syndrome X, insulin resistance syndrome, and metabolic syndrome ) is a condition in which a group of risk factors for
More informationEpidemiology of Hypertension 陈 奕 希 3120000591 李 禾 园 3120000050 王 卓 3120000613
Epidemiology of Hypertension 陈 奕 希 3120000591 李 禾 园 3120000050 王 卓 3120000613 1 Definition Hypertension is a chronic medical condition in which the blood pressure in the arteries is elevated. 2 Primary
More informationNCT00272090. sanofi-aventis HOE901_3507. insulin glargine
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationDiabetes and Hypertension Care For Adults in Primary Care Settings
and Hypertension Care For Adults in Primary Care Settings What is Type 2? The carbohydrates including sugar and starch which we take become glucose after digestion. It will then be absorbed by the small
More informationLIPID AND LIPOPROTEIN METABOLISM. OBJECTIVES: After completion of this lesson, the participant will be able to:
LIPID AND LIPOPROTEIN METABOLISM OBJECTIVES: After completion of this lesson, the participant will be able to: 1. Define the following terms : a. Lipid b. Lipoprotein c. Apolipoprotein d. Endogenous e.
More informationDavid Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010
David Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010 Objectives At the end of the talk, the participants will be able to: 1. Identify the increasing prevalence of type 2 diabetes
More informationTreating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference
Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group Learning Objectives To accurately make the diagnosis of pre-diabetes/metabolic syndrome To understand the prevalence
More informationHigh Blood Cholesterol What you need to know
National Cholesterol Education Program High Blood Cholesterol What you need to know Why Is Cholesterol Important? Your blood cholesterol level has a lot to do with your chances of getting heart disease.
More informationDIET AND EXERCISE STRATEGIES FOR WEIGHT LOSS AND WEIGHT MAINTENANCE
DIET AND EXERCISE STRATEGIES FOR WEIGHT LOSS AND WEIGHT MAINTENANCE 40 yo woman, BMI 36. Motivated to begin diet therapy. Which of the following is contraindicated: Robert B. Baron MD MS Professor and
More informationNancy S. Swayze. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume V, 2000-2001. A. Background
Efficacy Of Insulin Sensitizing Agents In Subjects With Metabolic Syndrome X And Impaired Glucose Tolerance After 6 Months Of Diet And Exercise Therapy Nancy S. Swayze A. Background Impaired glucose tolerance
More informationRole of Body Weight Reduction in Obesity-Associated Co-Morbidities
Obesity Role of Body Weight Reduction in JMAJ 48(1): 47 1, 2 Hideaki BUJO Professor, Department of Genome Research and Clinical Application (M6) Graduate School of Medicine, Chiba University Abstract:
More informationJNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates. January 30, 2014
JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates January 30, 2014 GOALS Review key recommendations from recently published guidelines on blood pressure and cholesterol management Discuss
More informationThe menopausal transition usually has three parts:
The menopausal transition usually has three parts: Perimenopause begins several years before a woman s last menstrual period, when the ovaries gradually produce less estrogen. In the last 1-2 years of
More informationLong-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study
ORIGINAL PAPER Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study A. M. Traish, 1 A. Haider, 2 G. Doros, 3 F. Saad
More informationAssessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study
European Journal of Clinical Investigation (2007) 37, 925 932 DOI: 10.1111/j.1365-2362.2007.01888.x Blackwell Publishing Ltd Review Assessing risk of myocardial infarction and stroke: new data from the
More informationHEALTH CLAIMS ON PECTINS APPROVED BY EFSA
HEALTH CLAIMS ON PECTINS APPROVED BY EFSA Scientific Opinion on the substantiation of health claims related to pectins and reduction of post-prandial glycaemic responses (ID 786) and maintenance of normal
More informationDiabetes mellitus is a chronic condition that occurs as a result of problems with the production and/or action of insulin in the body.
International Diabetes Federation Diabetes Background Information Diabetes mellitus is a chronic condition that occurs as a result of problems with the production and/or action of insulin in the body.
More informationHormone Replacement Therapy : The New Debate. Susan T. Hingle, M.D.
Hormone Replacement Therapy : The New Debate Susan T. Hingle, M.D. Background Hormone replacement therapy (HRT) is extensively used in the United States, especially for: *treatment of menopausal symptoms
More informationAbsolute cardiovascular disease risk
Guidelines for the management of Absolute cardiovascular disease risk An initiative of the National Vascular Disease Prevention Alliance About the National Vascular Disease Prevention Alliance The National
More informationEUROPEAN JOURNAL EPIDEMIOLOGY
Eur. J. Epidemiol. 0392-2990 March 1993, p. 134-139 EUROPEAN JOURNAL OF EPIDEMIOLOGY Vol. 9, No. 2 HIGH BI~OOD PRESSURE AND THE INCIDENCE OF NON-INSULIN I)EPENDENT DIABETES MELI,ITUS: FINDINGS IN A 11.5
More informationType 1 Diabetes ( Juvenile Diabetes)
Type 1 Diabetes W ( Juvenile Diabetes) hat is Type 1 Diabetes? Type 1 diabetes, also known as juvenile-onset diabetes, is one of the three main forms of diabetes affecting millions of people worldwide.
More informationEvidence-Based Secondary Stroke Prevention and Adherence to Guidelines
Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines Mitchell S.V. Elkind, MD, MS Associate Professor of Neurology Columbia University New York, NY Presenter Disclosure Information Mitchell
More informationDiabetes and Obesity in Children. Janie Berquist, RN, BSN, MPH, CDE Children s Mercy Hospitals and Clinics Kansas City, MO
Diabetes and Obesity in Children Janie Berquist, RN, BSN, MPH, CDE Children s Mercy Hospitals and Clinics Kansas City, MO Diabetes and Obesity in Children What is Diabetes? How are Diabetes and Obesity
More informationMain Effect of Screening for Coronary Artery Disease Using CT
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
More informationPRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION
Hull & East Riding Prescribing Committee PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION For guidance on Primary Prevention please see NICE guidance http://www.nice.org.uk/guidance/cg181
More information